

Supplementary Table 1. Baseline characteristics of hypertensive population tested for SARS-CoV-2 infection, matched for each class of antihypertensive medication

Characteristic	Control (n = 20,178)	RAS blocker (n = 20,178)	CCB (n = 22,560)	Control (n = 22,560)	p value	Control (n = 11,770)	BB (n = 11,770)	p value	Control (n = 9,342)	Diuretics (n = 9,342)	p value
Age, yr	68.9 ± 13.7 10,230 (50.7)	68.9 ± 13.7 10,205 (50.6)	68.3 ± 13.8 11,502 (51.0)	68.3 ± 13.8 11,507 (51.0)	0.783	69.5 ± 13.7 6,291 (53.5)	69.4 ± 13.8 6,311 (53.6)	0.466	69.3 ± 13.6 4,300 (46.0)	69.2 ± 13.7 4,293 (46.0)	0.537
Male sex	2,419 (12.0)	2,397 (11.9)	2,517 (11.2)	2,460 (10.9)	0.803	2,480 (21.1)	2,480 (21.1)	0.962	1,067 (11.4)	1,035 (11.1)	0.918
Heart failure	842 (4.2)	858 (4.3)	849 (3.8)	817 (3.6)	0.736	773 (6.6)	773 (6.6)	0.392	334 (3.6)	303 (3.2)	0.459
Prior MI	8,720 (43.2)	8,729 (43.3)	9,765 (43.3)	9,763 (43.3)	0.692	6,148 (52.2)	6,146 (52.2)	0.424	4,232 (45.3)	4,225 (45.2)	0.211
Diabetes	3,527 (17.5)	3,530 (17.5)	3,785 (16.8)	3,780 (16.8)	0.928	2,275 (19.3)	2,271 (19.3)	0.985	1,741 (18.6)	1,698 (18.2)	0.918
COPD or asthma	-	-	13,367 (59.3)	13,318 (59.0)	0.969	4,849 (50.2)	4,849 (50.2)	0.970	8,142 (87.2)	8,142 (87.2)	0.417
RAS blocker	-	-	-	-	-	6,534 (55.5)	6,541 (55.6)	0.639	5,213 (55.8)	4,068 (56.5)	1.000
CCB	10,370 (51.4)	10,379 (51.4)	4,430 (19.6)	4,406 (19.5)	0.929	-	-	0.927	2,256 (24.2)	2,230 (23.9)	0.369
Beta-blocker	4,233 (21.0)	4,224 (20.9)	3,091 (13.7)	3,132 (13.9)	0.912	1,714 (14.6)	1,688 (14.3)	0.776	-	-	0.656
Diuretics	1,032 (5.1)	1,032 (5.1)	605 (2.7)	598 (2.7)	1.00	-	-	0.576	-	-	-
SARS-CoV-2 (+)	472 (2.3)	547 (2.7)	605 (2.7)	598 (2.7)	0.017	271 (2.3)	243 (2.1)	0.838	252 (2.7)	281 (3.0)	0.203

Values are presented as mean ± SD or number (%).

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RAS, renin-angiotensin system; CCB, calcium-channel blocker; BB, beta-blocker; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.